Updated hourlyHourly refreshMon, Oct 26, 2026
Press Release Database
Recent press releases, indexed by topic.
Biotech & pharma
The community-acquired bacterial pneumonia market is poised for continued growth, driven by the substantial global disease burden, increasing hospitalization rates, an aging population, rising prevalence of comorbidities, and the growing challenge of antimicrobial resistance....
Sep 7 · 14:31·PR Newswire
Biotech & pharma
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Sep 7 · 14:31·GlobeNewswire
Healthcare · Biotech & pharma
Delray Beach, FL, Sept. 07, 2026 -- MarketsandMarkets™ projects the global injectable drug delivery market will grow from USD 690.23 billion in 2025 to USD 1,034.78 billion by 2030, at a CAGR of 8.4% during the forecast period. Market growth is fueled by the rising prevalence of chronic diseases such as diabetes, cancer, cardiovascular diseases, and autoimmune disorders, increasing demand for biologics, advancements in injectable formulations, and the growing adoption of patient-friendly drug delivery devices including prefilled syringes, autoinjectors, pen injectors, wearable injectors, and needle-free systems.
Sep 7 · 14:30·GlobeNewswire
Finance · Biotech & pharma
New York, New York--(September 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
Sep 7 · 13:38·Newsfile
Food & drink · Biotech & pharma
– 5,600 participants from 19 countries discuss global bio innovation and the path forward – – Strengthened global regulatory cooperation, with a total of 23 meetings held with overseas regulators and industry, including 5 regulatory cooperation meetings – SEOUL, South Korea, Sept. 7, 2026...
Sep 7 · 12:00·PR Newswire
Finance · Healthcare
COPENHAGEN, Denmark, Sept. 07, 2026 -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for Paediatric Endocrinology (ESPE) being held September 8-10, 2026, in Marseille, France. Updates will include a podium presentation of the first sentinel cohort data from the pivotal reACHin Trial of TransCon CNP (navepegritide) in infants with achondroplasia aged 0 to <2 years.
Sep 7 · 11:00·GlobeNewswire
Biotech & pharma
STEP Young data show 40.4% of children treated with semaglutide and lifestyle modification were no longer classified as having obesity.
Sep 7 · 10:00·GlobeNewswire
Biotech & pharma
Dublin, Sept. 07, 2026 -- The "Stem Cell Therapy Market by Source of Stem Cell, Origin of Stem Cell, Type of Stem Cell, Lineage of Stem Cell, Route of Administration, Therapeutic Area, End Users and Geographical Regions - Trends and Global Forecast Till 2035" has been added to ResearchAndMarkets.com's offering.
Sep 7 · 08:59·GlobeNewswire
Industrial · Biotech & pharma
YANTAI, China, Sept. 7, 2026 -- CelluPro, a biotechnology company specializing in serum-free cell culture media and bioprocess solutions, has achieved EXCiPACT™ GMP Certification for Pharmaceutical Auxiliary Materials (PAMs), becoming the first Chinese cell culture media...
Sep 7 · 06:00·PR Newswire
Finance · Biotech & pharma
New York, New York--(September 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
Sep 7 · 02:17·Newsfile
Finance · AI
SHANGHAI, Sep 7, 2026 - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196.SH; 02196.HK) today announced an H share repurchase plan, under which the company intends to repurchase its H shares with an aggregate amount of up to HK$1 billion. The shares so repurchased will be cancelled or held as treasury shares. Taking concrete action to respond to market concerns, this repurchase plan demonstrates management's unwavering confidence in the company's intrinsic value. The plan has come into effect and will be implemented as soon as practicable. As a continuation of the Group's long-term value management toolkit, the company will dynamically evaluate and execute repurchases on a rolling basis in response to market conditions, establishing a normalized mechanism for shareholder returns.
In the first half of 2026, Fosun Pharma's earnings quality continued to improve, with revenue contributions from innovative drugs and international markets steadily increasing. Core operational indicators further consolidated upon the foundation of 2025:
- Revenue: RMB 20,442 million, up 4.75% year-on-year;
- Profit attributable to shareholders of the listed company, net of non-recurring gains and losses: RMB 1,144 million, up 19.09% year-on-year;
- Net cash generated from operating activities: RMB 2,424 million, up 13.59% year-on-year.
The repurchase will be primarily funded by proceeds from the disposal of approximately 6.00% equity interest in Gland Pharma, with total consideration of around US$294 million. Upon completion of the transaction, Fosun Pharma remains the promoter of Gland Pharma with an approximate 45.76% equity interest, and Gland Pharma will continue to be consolidated into Fosun Pharma's financial statements. Net proceeds from the transaction will primarily be allocated toward the Company's R&D investments, share repurchases, and the repayment of interest-bearing debts. As the controlling shareholder, Fosun Pharma remains fully confident in Gland Pharma's long-term development and its enduring role as a key engine for overseas value creation.
Looking ahead, Fosun Pharma will stay focused on innovation and globalization, accelerating the R&D progress and commercialization of its major pipeline candidates. This repurchase program is intended to convey the Company’s confidence in its intrinsic value and to generate sustainable returns for shareholders.
About Fosun Pharma
Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. With the mission of Better Health for Families Worldwide, we focus on developing innovative medicines, medical technologies and diagnostics as well as delivering healthcare services. Through our business partner Sinopharm Group, we have also established pharmaceutical distribution network, built a comprehensive pharmaceutical and healthcare ecosystem.
Fosun Pharma is dedicated to innovation and globalization. The company has established a global R&D innovation system targeting at unmet medical needs. Our strategic focus is on key therapeutic areas including oncology, immunology and inflammation, neurodegenerative diseases, and selected cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. These efforts have strengthened our early-stage innovative portfolios and accelerated the transformation of scientific discoveries to drug development. Our innovative products are now available in more than 90 countries and regions worldwide, including major markets across China, the United States, Europe, Africa, India and Southeast Asia.
Looking ahead, guided by the strategy of “Innovation Driven, Deep Globalization, and AI Embracement”, Fosun Pharma remains committed to its core values: Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership. We strive to become a leading global healthcare innovation integrator, ensuring that the benefits of medical innovation reach more patients worldwide, and contribute to safeguarding human health.
For more information about the Group, please visit the company website:
https://www.fosunpharma.com/en/
Sep 6 · 23:48·ACN Newswire
Healthcare · Biotech & pharma
-- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection -- -- Robust...
Sep 6 · 23:07·PR Newswire